The EC approval also now means that Libtayo can be used to treat certain patients across four types of cancer within the European Union: advanced squamous cell carcinoma (SCC), advanced basal cell ...

The study enrolled women with squamous cell carcinoma and adenocarcinoma forms of cervical cancer, and the death rate in those subgroups was reduced by 27% and 44%, respectively, with Libtayo.

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care ... in the U.S. The most common type of penile ...

Squamous cell cancer (SCC) is a type of skin cancer. To determine the severity of SCC, doctors use a staging system. There are five stages in total, ranging from 0 to 4. SCC stages describe the ...

Patients with a rare disease called mucous membrane pemphigoid are at risk of developing squamous cell carcinoma and basal cell carcinoma, finds a new study.

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

in the treatment of basal cell carcinoma (BCC), with positive data outcomes. The study included patients who had relapsed after standard therapies and had no other treatment options. Among them, three ...

Notably, 27.3% (6 patients) had also failed second-line PD-1 inhibitors such as Libtayo or Keytruda ... cx-4945-in-the-treatment-of-basal-cell-carcinoma-302418218.html ...